Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads

Executive Summary

Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.

Advertisement

Related Content

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies
Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?
Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal
INTERVIEW: Dong-A Seeks Partners For Global Expansion Push

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel